Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072059 · ClinicalTrials.gov registry record · Phase 2
Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00072059: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00072059 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072059, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Ro 50-3821 may stimulate red blood cell production and treat anemia in patients who are receiving antineoplastic therapy for non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying six different regimens of Ro 50-3821 to compare how well they work in treating anemia in patients who are receiving antineoplastic therapy for stage IIIB or stage IV non-small cell lung cancer.
Interventions
- BIOLOGICAL methoxy polyethylene glycol epoetin beta
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
What the finished NCT00072059 record still lists
NCT00072059 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which methoxy polyethylene glycol epoetin beta is the first listed.
NCT00072059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00072059 about?
NCT00072059 is a clinical study titled "Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Ro 50-3821 may stimulate red blood cell production and treat anemia in patients who are receiving antineoplastic therapy for non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying six different regimens of Ro 50-3821 to compare how well they work in treating anem...
What is the current status of trial NCT00072059?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-07. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00072059?
The interventions under investigation include: methoxy polyethylene glycol epoetin beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072059?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia